Association of HindIII SNP in Intron 19 of the FVIII gene with musculoskeletal complications in pediatric patients with hemophilia A
DOI:
https://doi.org/10.52783/jns.v14.3344Keywords:
Hemophilia A, HindIII polymorphism, FVIII gene, musculoskeletal complications, family history, genetic markers, PCR-RFLPAbstract
Hemophilia A (HA) is the most common congenital X-linked coagulopathy caused by mutations in the FVIII gene, inherited in a recessive manner. Despite its well-established clinical characteristics, approximately 30% of HA cases are sporadic. Musculoskeletal complications, such as recurrent joint bleedings, significantly impact patient quality of life. This study aimed to investigate the relationship between the HindIII polymorphism in the FVIII gene and musculoskeletal complications, as well as its association with family history in HA patients from East Java, Indonesia. A total of 63 patients were analyzed using the PCR-RFLP method. The findings revealed no significant correlation between the HindIII SNP and musculoskeletal complications (P = 0.720) or family history (P = 0.542). These results suggest that the HindIII polymorphism does not serve as a determinant factor for musculoskeletal complications or family history in this population. Further studies with larger sample sizes and advanced molecular techniques are needed to explore the role of the HindIII polymorphism in hemophilia A.
Downloads
Metrics
References
Bhattacharya, P., et al. (2019). Polymorphic markers for carrier detection in hemophilia A families: A study from India. Blood Coagulation & Fibrinolysis, 30(4), 278-285. https://doi.org/10.1097/MBC.0000000000000825
Biguzzi, E., Galen, K. van, & Kadir, R. A. (2019). Genetics 101: understanding transmission and genetic testing of inherited bleeding disorders. The Journal of Haemophilia Practice, 6(2), 10–17. https://doi.org/10.17225/jhp00139
Campos, L., et al. (2018). Intronic SNPs in the FVIII gene and their association with plasma FVIII levels. Thrombosis Research, 164, 79-85.
Castro, H. E., Briceño, M. F., Casas, C. P., Rueda, J. D. (2014). The history and evolution of the clinical effectiveness of haemophilia type A treatment: A systematic review. Indian Journal of Hematology and Blood Transfusion, 30, 1–11.
Doncel, S. S., Díaz Mosquera, G. A., Cortes, J. M., Agudelo Rico, C., Meza Cadavid, F. J., & Peláez, R. G. (2023). Haemophilia A: A review of clinical manifestations, treatment, mutations, and the development of inhibitors. Hematology Reports, 15(1), 130–150. https://doi.org/10.3390/hematolrep15010014
Franchini, M., & Mannucci, P. M. (2016). The safety of pharmacologic options for the treatment of persons with hemophilia. Expert Opinion on Drug Safety, 15(10), 1391–1400. https://doi.org/10.1080/14740338.2016.1208747
Goodeve, A. (2015). The genetic basis of hemophilia A and B. Haemophilia, 21(Suppl 1), 1-8.
Kumar, P., Henikoff, S., & Ng, P. C. (2019). Predicting the effects of coding non-synonymous variants on protein function using the PCR-RFLP method. Nucleic Acids Research, 47(2), 1-12.
Lobet, S., Hermans, C., & Lambert, C. (2021). Optimal management of hemophilic arthropathy and hematomas. Journal of Clinical Medicine, 10(5), 1043.
Mahlangu, J. (2019). Emicizumab for the prevention of bleeds in hemophilia A. Expert Opinion on Biological Therapy, 19(8), 753–761. https://doi.org/10.1080/14712598.2019.1626370
Ramezani, M., et al. (2016). Genetic markers in hemophilia A: Utility of SNP HindIII in carrier detection. Haematologica, 101(3), 234-241.
Rodriguez-Merchan, E. C. (2010). Musculoskeletal complications of hemophilia. HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery, 6(1), 37–42. https://doi.org/10.1007/s11420-009-9140-9
Sambrook, J., & Russell, D. W. (2001). Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press.
Schep, S. J., Boes, M., Schutgens, R. E. G., & van Vulpen, L. F. D. (2019). An update on the ‘danger theory’ in inhibitor development in hemophilia A. Expert Review of Hematology, 12(5), 335–344. https://doi.org/10.1080/17474086.2019.1604213
Singh, M., Gupta, L. K., Aneja, G. K., Dayal, R., Kumar, N., Singh, S. P., et al. (2020). Hemophilia in children: A clinico-epidemiological profile and review. Pediatrics Review International Journal of Pediatric Research, 7(2), 66-7.
Soucie, J. M., Miller, C. H., Kelly, F. M., et al. (2018). The surveillance of hemophilia in the United States: Challenges and findings. American Journal of Hematology, 93(7), 940-948.
Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., et al. (2020). Guidelines for the management of hemophilia. Haemophilia, 26(Suppl 6), 1-158.
Spena, S., Garagiola, I., Cannavò, A., Mortarino, M., Mannucci, P. M., Rosendaal, F. R., Peyvandi, F., Sippet Study Group. (2018). Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 16, 778–790.
Vantaku, V. V., K., J. P., M., M. M., & D., M. (2023). Clinical profile of hemophilia children admitted in a tertiary care hospital in South India: A cross-sectional study. International Journal of Contemporary Pediatrics, 10(11), 1652–1657. https://doi.org/10.18203/2349-3291.ijcp20233233
World Federation of Hemophilia (WFH). (2020). WFH guidelines for the management of hemophilia (3rd ed.). Montreal, Canada: World Federation of Hemophilia.
Zhou, Y., Li, Z., Liu, G., Chen, Z., Yao, W., Li, G., Zhen, Y., Cheng, X., Ai, D., Huang, K., Cao, W., & Wu, R. (2024). Cost-effectiveness analysis of prophylaxis versus on-demand treatment for children with moderate or severe hemophilia A in China. Clinical Therapeutics, 46(12), 1010–1015. https://doi.org/10.1016/j.clinthera.2024.09.003
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
